Spannagl M, Keller R, Schramm W
Internal Clinic Innenstadt, Munich University, FRG.
Folia Haematol Int Mag Klin Morphol Blutforsch. 1989;116(6):879-85.
The in vitro experiments show that the anticoagulant affect of a new AT III-Heparin-complex preparation in plasma is similar to heparin. The in vivo experiments indicate that the thrombin inhibition is even improved by using the complex preparation, because the aPTT values after complex treatment remained stable for more than one hour in the desired range. Bleeding complications are less likely after complex treatment, because much smaller maximum aPTT values are reached. The prolonged half life of the complex preparation possibly allows a reduced and more accurate dosage.
体外实验表明,一种新型抗凝血酶III-肝素复合物制剂在血浆中的抗凝作用与肝素相似。体内实验表明,使用该复合物制剂可进一步增强对凝血酶的抑制作用,因为复合物治疗后的活化部分凝血活酶时间(aPTT)值在所需范围内保持稳定超过一小时。复合物治疗后出血并发症的可能性较小,因为达到的最大aPTT值要小得多。复合物制剂延长的半衰期可能允许减少剂量并实现更精确的给药。